Product Description
6B11mini-ovarian-cytokine-induced-killer cells
Mechanisms of Action: Cell Therapy
Novel Mechanism: No
Modality: Cell Therapy
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Peking University
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Ovarian Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
6B11-OCIK-I | P1 |
Unknown status |
Ovarian Cancer |
2022-12-30 |
|
CTR20171659 | P1 |
Suspended |
Ovarian Cancer |
None |
|
CTR20190733 | P1 |
Recruiting |
Ovarian Cancer |
None |